

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Sommadossi <i>et al.</i>	Confirmation No.:	8280
Serial No.:	10/602,142	Art Unit:	1623
Filed:	June 20, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No:	11874-044-999
		(CAM:	417451-999044)
			IDX 1007 CON 2

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.56**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.


Copies of References B01 to B89 and C01 to C173 are submitted herewith. References A01 to A136 are U.S. patents and U.S. published applications. Therefore, copies of these references are not submitted herewith, pursuant to 37 C.F.R. § 1.98(a)(2)(ii). References A137 to A139 are pending unpublished U.S. patent applications available at the USPTO's private PAIR system. Therefore, pursuant to 1287 OG 163, copies of these applications are not submitted herewith.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application. Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) after the filing of a Request for Continued Examination under 37 C.F.R. §1.114, therefore, no fee is believed to be due with this submission. However, pursuant to 37 C.F.R. §1.136 (a)(3), the Commissioner is authorized to charge all required fees, fees under 37 C.F.R. § 1.17 and all required extension of time fees, or credit any overpayment, to Jones Day Deposit Account No. 503013 (ref. no. 417451-999044).

Respectfully submitted,

Date: November 8, 2007

  
*For:* Mark D. Kafka Reg. No. 59,569

Dale L. Rieger Reg. No. 43,045

**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(858) 314-1200